Treatment of Non-small Cell Lung Cancer (NSCLC)

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2013 Oct 9

PMID 24102012

Citations 148

Authors

Konstantinos Zarogoulidis

Paul Zarogoulidis

Kaid Darwiche

Efimia Boutsikou

Nikolaos Machairiotis

Kosmas Tsakiridis

Nikolaos Katsikogiannis

Ioanna Kougioumtzi

Ilias Karapantzos

Haidong Huang

Dionysios Spyratos

Affiliations

Soon will be listed here.

Abstract

Radical surgery is the standard of care for fit stage I non-small cell lung cancer (NSCLC) patients. Adjuvant treatment should be offered only as part of an investigation trial. Stage II and IIIA adjuvant cisplatin-based chemotherapy remains the gold standard for completely resected NSCLC tumors. Additionally radiotherapy should be offered in patients with N2 lymph nodes. In advanced stage IIIB/IV or inoperable NSCLC pts, a multidisciplinary treatment should be offered consisted of 4 cycles of cisplatin-based chemotherapy plus a 3(rd) generation cytotoxic agent or a cytostatic (anti-EGFR, anti-VEGFR) drug.

Citing Articles

Prediction of PD-L1 tumor positive score in lung squamous cell carcinoma with H&E staining images and deep learning.

Wang Q, Deng X, Huang P, Ma Q, Zhao L, Feng Y Front Artif Intell. 2025; 7:1452563.

PMID: 39759385 PMC: 11695341. DOI: 10.3389/frai.2024.1452563.

Precision Nanomedicine: Lapatinib-Loaded Chitosan-Gold Nanoparticles Targeting LINC01615 for Lung Cancer Therapy.

Rezaei Aghdam H, Peymani M, Salehzadeh A, Rouhi L, Zarepour A, Zarrabi A AAPS J. 2024; 27(1):4.

PMID: 39562465 DOI: 10.1208/s12248-024-00990-y.

Mitochondrial VDAC1 Silencing in Urethane-Induced Lung Cancer Inhibits Tumor Growth and Alters Cancer Oncogenic Properties.

Melnikov N, Pittala S, Shteinfer-Kuzmine A, Shoshan-Barmatz V Cancers (Basel). 2024; 16(17).

PMID: 39272828 PMC: 11393979. DOI: 10.3390/cancers16172970.

Impact of interplay effects on spot scanning proton therapy with motion mitigation techniques for lung cancer: SFUD versus robustly optimized IMPT plans utilizing a four-dimensional dynamic dose simulation tool.

Yamano A, Inoue T, Yagihashi T, Yamanaka M, Matsumoto K, Shimo T Radiat Oncol. 2024; 19(1):117.

PMID: 39252032 PMC: 11385833. DOI: 10.1186/s13014-024-02518-2.

Oral inhalation of dacomitinib nanocarriers as a therapeutic strategy for non-small cell lung cancer.

Rongala D, Patil S, Kunda N Nanomedicine (Lond). 2024; 19(18-20):1601-1613.

PMID: 39073842 PMC: 11389738. DOI: 10.1080/17435889.2024.2370225.

References

Natale R . A phase I/II trial of combination paclitaxel and carboplatin in advanced or metastatic non-small cell lung cancer: preliminary results of an ongoing study. Semin Oncol. 1995; 22(6 Suppl 15):34-7. View

Boutsikou E, Kontakiotis T, Zarogoulidis P, Darwiche K, Eleptheriadou E, Porpodis K . Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer. Onco Targets Ther. 2013; 6:125-34. PMC: 3589083. DOI: 10.2147/OTT.S42245. View

Ramalingam S, Dahlberg S, Langer C, Gray R, Belani C, Brahmer J . Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008; 26(1):60-5. DOI: 10.1200/JCO.2007.13.1144. View

Zarogoulidis K, Kontakiotis T, Hatziapostolou P, Fachantidou E, Delis D, Goutsikas J . A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer. Lung Cancer. 2001; 32(3):281-7. DOI: 10.1016/s0169-5002(00)00226-9. View

Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346(2):92-8. DOI: 10.1056/NEJMoa011954. View

Kelly K, Pan Z, Murphy J, Huffman D, Bunn Jr P . A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 1997; 3(7):1117-23. View

Creaven P, Raghavan D, Pendyala L, Loewen G, Kindler H, Berghorn Jr E . Paclitaxel and carboplatin in early phase studies: Roswell Park Cancer Institute experience in the subset of patients with lung cancer. Semin Oncol. 1997; 24(4 Suppl 12):S12-138-S12-143. View

Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A . Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000; 18(13):2529-36. DOI: 10.1200/JCO.2000.18.13.2529. View

Giaccone G, Herbst R, Manegold C, Scagliotti G, Rosell R, Miller V . Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol. 2004; 22(5):777-84. DOI: 10.1200/JCO.2004.08.001. View

10.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

11.

Woods R, Williams C, Levi J, Page J, Bell D, Byrne M . A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer. 1990; 61(4):608-11. PMC: 1971367. DOI: 10.1038/bjc.1990.135. View

12.

Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O . Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2005; 23(13):2937-45. DOI: 10.1200/JCO.2005.04.016. View

13.

Robinson L, Ruckdeschel J, Wagner Jr H, Stevens C . Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132(3 Suppl):243S-265S. DOI: 10.1378/chest.07-1379. View

14.

Smith I, OBrien M, Talbot D, Nicolson M, Mansi J, Hickish T . Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001; 19(5):1336-43. DOI: 10.1200/JCO.2001.19.5.1336. View

15.

Wozniak A, Crowley J, Balcerzak S, Weiss G, Spiridonidis C, Baker L . Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998; 16(7):2459-65. DOI: 10.1200/JCO.1998.16.7.2459. View

16.

Crino L, Scagliotti G, Ricci S, de Marinis F, Rinaldi M, Gridelli C . Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol. 1999; 17(11):3522-30. DOI: 10.1200/JCO.1999.17.11.3522. View

17.

Chansky K, Sculier J, Crowley J, Giroux D, Meerbeeck J, Goldstraw P . The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009; 4(7):792-801. DOI: 10.1097/JTO.0b013e3181a7716e. View

18.

Stathopoulos G, Veslemes M, Georgatou N, Antoniou D, Giamboudakis P, Katis K . Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. Ann Oncol. 2004; 15(7):1048-55. DOI: 10.1093/annonc/mdh260. View

19.

Langer C, Millenson M, Rosvold E, Litwin S, McAleer C, Bonjo C . Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network. Semin Oncol. 1997; 24(4 Suppl 12):S12-81-S12-88. View

20.

Roychowdhury D, Desai P, Zhu Y . Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a phase II study in advanced non-small cell lung cancer. Semin Oncol. 1997; 24(4 Suppl 12):S12-37-S12-40. View